Search Results
Results found for "Chris De Graaf"
- Embark on a GPCR Adventure: Your Weekly Research Expedition! | Oct 21-27, 2024
Dimerization: Unveiling Its Role in Receptor Function and Signaling Sonja Peter , Brian Bender , Chris De Graaf for their excellent work on Comparative Study of Allosteric GPCR Binding Sites and Their Ligandability
- Embark on a GPCR Adventure: Your Weekly Research Expedition! | Oct 21-27, 2024
Dimerization: Unveiling Its Role in Receptor Function and Signaling Sonja Peter , Brian Bender , Chris De Graaf for their excellent work on Comparative Study of Allosteric GPCR Binding Sites and Their
- Unlocking the Future of Medicine: Advancements in GPCR Research
This week's highlight includes congrats to Omolade Otun, Chris de Graaf, Cherine Bechara, et al. for
- Ono Enters into Collaboration Agreement with Domain Therapeutics and Université de Montréal for ...
April 2022 Ono Enters into Collaboration Agreement with Domain Therapeutics and Université de Montréal (Strasbourg, France; CEO: Pascal Neuville; “Domain”) and Université de Montréal (Québec, Canada; “UdM
- Dr. Tim De Groof - Dr. GPCR Podcast
Tim De Groof! It’s not often when you get the best of both worlds - nano-bodies and #GPCRs.
- Michel Bouvier appointed Knight of the Ordre national du Québec
the Department of Biochemistry and Molecular Medicine of the Faculty of Medicine of the Université de
- Sosei Heptares Confirms Senior Leadership Changes to Drive the Company Through the Next Stage ...
Chris Cargill appointed as President and Chief Executive Officer • Dr.
- Is Your GPCR Drug Discovery Program Built for Breakthroughs or Breakdowns?
This is the essence of de-risking GPCR programs through operational excellence. your drug discovery process from a series of disconnected efforts into a seamless, predictable, and de-risked Learn to translate your program’s internal operational precision into a compelling, de-risked narrative
- Artificial intelligence – faster, smarter, cheaper GPCR drug discovery
De novo drug design: AI algorithms can generate new molecules with desired properties, such as binding chemical space, limiting their ability to identify truly novel chemotypes”(Thomas, Smith, O’Boyle, de Graaf & Bender, 2021) and 4) limit of input data can lead to a phenomenon called “the burden of sequence
- From Lab Bench to Boardroom: The Unexpected Path of a Medicinal Chemist
A postdoc in Santiago de Compostela introduced her to GPCRs, and from there, things escalated quickly
- Inside Out: Mapping GPCRs from Membrane Codes to Market Moves
conversation dives deep into the tools now transforming receptor biology—and how they’re being used to de-orphanize
- 📰 GPCR Weekly News, October 9 to 15, 2023
success Sosei and PharmEnable extend neurological disease drugs hunt Sosei Heptares’ President & CEO Chris
- 📰 GPCR Weekly News
INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease Chris
- Adhesion GPCR Consortium Newsletter - May 2024
Member Profile Antony Boucard Professor Centro de Investigación y de Estudios Avanzados del IPN (Cinvestav AB: Favorite Taco: Taco de suadero (pronounced swa-day-ro), fatty, with meat caramelized in its own fat
- 📰 GPCR Weekly News, October 16 to 22, 2023
Topline Safety and Tolerability Data from Proof-of-Concept Studies Sosei Heptares’ President & CEO Chris
- Dr. GPCR and Celtarys Research Join Forces to Expand Access to Innovative GPCR Tools
Boston, MA and Santiago de Compostela, Spain — [June 3rd, 2025] — Dr.
- 📰 GPCR Weekly News, February 13 to 19, 2023
From the scientist’s view: a conversation with … Chris Tate AI is dreaming up drugs that no one has ever
- Pharmacology at Your Fingertips: Terry’s Corner Launches
GPCR consulting that cuts through the noise, designing assay cascades, setting go/no-go points, and de-risking
- Class B1 GPCR Dimerization: Unveiling Its Role in Receptor Function and Signaling
Graaf, C., et al., Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March
- Hop in the Time Machine with GPCR: Unraveling the Future of Research! ⦿ Nov 24 - Dec 1, 2024
Madelyn N Moore , Kelsey L Person , Abigail Alwin , Campbell Krusemark , Ezequiel Marron Fernandez de loss after a year, with no plateau INAUGURATION OF AELIS FARMA NEW LABORATORY at Institut Européen de
- Conjugation Strategies for Probe Development
.; Henry De Villeneuve, C.; Moraillon, A.; Ozanam, F.; Gabouze, N.; Djebbar, S.
- How Fast Does a Drug Work?
Your pipeline depends on early, well-informed decisions that move promising candidates forward while de-prioritizing
- Applications of Fluorescent Probes in Confocal Imaging of GPCRs: From Live to Fixed Cells
Fluorescence Microscopy validation performed in the ONCOMET laboratory (Health Research Institute of Santiago de
- Fluorescence Polarization in GPCR Research
L, González A, Gioé-Gallo C, Mallo-Abreu A, Brea J, Loza MI, García-Rey A, García-Mera X, Gutiérrez-de-Terán
- Targeting GPCRs in the CNS: Advances in Drug Discovery Strategies
Source: Kim J, Choi C. 2018 Feb;98:222-232. doi: 10.1016/j.biopha.2017.12.056 Azam S, Haque ME, Jakaria M, Jo SH, Kim IS, Choi Cells. 2020 Feb 23;9(2):506. doi: 10.3390/cells9020506 Kim J, Choi C.
- 📰 GPCR Weekly News, March 6 to 12, 2023
Domain Therapeutics was nominated for the Trophée de l'Innovation Technologique (Technological Innovation
- Beyond Clearance: The Strategic Power of Irreversible Drug Binding
running early-stage programs, recognizing this decoupling early can sharpen dose optimization and de-risk
- Therapeutic validation of an orphan G protein‐coupled receptor
Therefore, matching a ligand to an orphan GPCRs, the process of de-orphanizing, is of great importance
- 📰 GPCR Weekly News, April 10 to 16, 2023
Michel Bouvier received the title of Doctor Honoris Causa from the Université de Montpellier Domain Therapeutics
- 🤯Mind-blowing GPCR Scoops! Discover the Latest Breakthroughs! ⦿ Nov 18 - 24, 2024
GPCR drugmaker Septerna amasses $288M in IPO Surrounded by AI bio giants, tiny startup Nabla Bio makes de


















